Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

BRIMONIDINE TARTRATE

BRIMONIDINE TARTRATE

Standard Dose
EQ 0.33% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary

Approval overview BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 209158 (ANDA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient BRIMONIDINE TARTRATE Form and strength GEL;TOPICAL - EQ 0.33% BASE Sponsor PADAGIS ISRAEL Submission history Latest submission status date: 2022-06-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 209158 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient BRIMONIDINE TARTRATE Form and strength GEL;TOPICAL - EQ 0.33% BASE Sponsor PADAGIS ISRAEL Submission history Latest submission status date: 2022-06-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.